Pneumon 2018, 31(4): 207- 213, Original Study
Assessing the budget impact of nintedanib for the treatment of idiopathic pulmonary fibrosis in the Greek healthcare setting
Authors Information

1University of Peloponnese, Corinth, Greece
2Health Policy Institute, Athens, Greece
3University of Athens, Athens, Greece



Idiopathic pulmonary fibrosis (IPF) is a rare, chronic lung disease with a high mortality rate. IPF affects about 5 million people worldwide with median survival being 2-5 years following diagnosis. Until recently, there was no licensed pharmacologic therapy available for IPF and patients were managed by best supportive care, that includes treatment with pirfenidone. In 2015, nintedanib was approved for the treatment of IPF. This study estimates the reimbursement of nintedanib and its budget impact on the National Organization for Health Care Services Provision (EOPPY). The budget impact of reimbursing nintedanib as part of already available treatment options corresponds to a maximum of 0.13% of annual total pharmaceutical expenditure. Therefore, it has a relatively low impact on the budget of EOPPY, while use of nintedanib was associated with a higher number of acute exacerbation events being avoided, thus providing additional cost savings to EOPPY.